KALV Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -361.39% compared to KalVista Pharmaceuticals, Inc.'s net margin of -12425.36%. KalVista Pharmaceuticals, Inc.'s return on equity of -243.25% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

KalVista Pharmaceuticals, Inc. has a consensus price target of $33.22, signalling upside risk potential of 100.86%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 360.96%. Given that Perspective Therapeutics, Inc. has higher upside potential than KalVista Pharmaceuticals, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than KalVista Pharmaceuticals, Inc..

KalVista Pharmaceuticals, Inc. has a beta of -0.144, which suggesting that the stock is 114.385% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.

KalVista Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

KalVista Pharmaceuticals, Inc. quarterly revenues are $13.7M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. KalVista Pharmaceuticals, Inc.'s net income of -$49.5M is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, KalVista Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals, Inc. is 57.38x versus 181.04x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Electromed, Inc. has a net margin of -361.39% compared to KalVista Pharmaceuticals, Inc.'s net margin of 12.65%. KalVista Pharmaceuticals, Inc.'s return on equity of -243.25% beat Electromed, Inc.'s return on equity of 18.89%.

KalVista Pharmaceuticals, Inc. has a consensus price target of $33.22, signalling upside risk potential of 100.86%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 31.48%. Given that KalVista Pharmaceuticals, Inc. has higher upside potential than Electromed, Inc., analysts believe KalVista Pharmaceuticals, Inc. is more attractive than Electromed, Inc..

KalVista Pharmaceuticals, Inc. has a beta of -0.144, which suggesting that the stock is 114.385% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.442%.

KalVista Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

KalVista Pharmaceuticals, Inc. quarterly revenues are $13.7M, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. KalVista Pharmaceuticals, Inc.'s net income of -$49.5M is lower than Electromed, Inc.'s net income of $2.1M. Notably, KalVista Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 29.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals, Inc. is 57.38x versus 3.65x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

InfuSystem Holdings, Inc. has a net margin of -361.39% compared to KalVista Pharmaceuticals, Inc.'s net margin of 6.19%. KalVista Pharmaceuticals, Inc.'s return on equity of -243.25% beat InfuSystem Holdings, Inc.'s return on equity of 9.93%.

KalVista Pharmaceuticals, Inc. has a consensus price target of $33.22, signalling upside risk potential of 100.86%. On the other hand InfuSystem Holdings, Inc. has an analysts' consensus of $14.20 which suggests that it could grow by 64.16%. Given that KalVista Pharmaceuticals, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe KalVista Pharmaceuticals, Inc. is more attractive than InfuSystem Holdings, Inc..

KalVista Pharmaceuticals, Inc. has a beta of -0.144, which suggesting that the stock is 114.385% less volatile than S&P 500. In comparison InfuSystem Holdings, Inc. has a beta of 1.680, suggesting its more volatile than the S&P 500 by 68.01%.

KalVista Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystem Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals, Inc. pays -- of its earnings as a dividend. InfuSystem Holdings, Inc. pays out -- of its earnings as a dividend.

KalVista Pharmaceuticals, Inc. quarterly revenues are $13.7M, which are smaller than InfuSystem Holdings, Inc. quarterly revenues of $36.5M. KalVista Pharmaceuticals, Inc.'s net income of -$49.5M is lower than InfuSystem Holdings, Inc.'s net income of $2.3M. Notably, KalVista Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while InfuSystem Holdings, Inc.'s PE ratio is 33.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals, Inc. is 57.38x versus 1.30x for InfuSystem Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Silvergate Capital has a net margin of -361.39% compared to KalVista Pharmaceuticals, Inc.'s net margin of --. KalVista Pharmaceuticals, Inc.'s return on equity of -243.25% beat Silvergate Capital's return on equity of --.

KalVista Pharmaceuticals, Inc. has a consensus price target of $33.22, signalling upside risk potential of 100.86%. On the other hand Silvergate Capital has an analysts' consensus of -- which suggests that it could fall by --. Given that KalVista Pharmaceuticals, Inc. has higher upside potential than Silvergate Capital, analysts believe KalVista Pharmaceuticals, Inc. is more attractive than Silvergate Capital.

KalVista Pharmaceuticals, Inc. has a beta of -0.144, which suggesting that the stock is 114.385% less volatile than S&P 500. In comparison Silvergate Capital has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

KalVista Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Silvergate Capital offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. KalVista Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Silvergate Capital pays out -- of its earnings as a dividend.

KalVista Pharmaceuticals, Inc. quarterly revenues are $13.7M, which are larger than Silvergate Capital quarterly revenues of --. KalVista Pharmaceuticals, Inc.'s net income of -$49.5M is higher than Silvergate Capital's net income of --. Notably, KalVista Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Silvergate Capital's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for KalVista Pharmaceuticals, Inc. is 57.38x versus -- for Silvergate Capital. Usually stocks with elevated PS ratios are considered overvalued.